(Z,R)-5-(2-(6-(8-fluoronaphthalen-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)-3-methylbutylidene)oxazolidine-2,4-dione

ID: ALA4784483

PubChem CID: 137487348

Max Phase: Preclinical

Molecular Formula: C23H19FN2O4

Molecular Weight: 406.41

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CC(C)[C@H](/C=C1\OC(=O)NC1=O)c1ccc(-c2ccc3cccc(F)c3c2)[nH]c1=O

Standard InChI:  InChI=1S/C23H19FN2O4/c1-12(2)16(11-20-22(28)26-23(29)30-20)15-8-9-19(25-21(15)27)14-7-6-13-4-3-5-18(24)17(13)10-14/h3-12,16H,1-2H3,(H,25,27)(H,26,28,29)/b20-11-/t16-/m0/s1

Standard InChI Key:  LJHNDLRPPVVCJF-VBNMEBLOSA-N

Molfile:  

 
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   34.0788  -13.4248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.0788  -14.2498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.7908  -14.6582    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.5029  -14.2498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.5029  -13.4248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.7908  -13.0082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.3610  -13.0159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.3650  -14.6633    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   36.2149  -14.6623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.2123  -15.4884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9253  -15.9018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9263  -14.2513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.6400  -14.6611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.6387  -15.4896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.3545  -15.9033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.0720  -15.4893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.0693  -14.6576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.3529  -14.2478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.6489  -13.4323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.9321  -13.0239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.6535  -14.2573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.3505  -13.4228    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   33.3556  -12.1867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.0673  -11.7696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.8234  -12.0967    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.3714  -11.4799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.9542  -10.7681    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.1485  -10.9451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.5316  -10.3972    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   36.1925  -11.5607    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  6  2  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  7  1  1  0
  2  8  2  0
  9 10  2  0
 10 11  1  0
 11 14  2  0
 13 12  2  0
 12  9  1  0
  4  9  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
  7 19  1  0
 19 20  1  0
 19 21  1  0
 18 22  1  0
  7 23  1  6
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 24  1  0
 28 29  2  0
 26 30  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4784483

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 406.41

Molecular Weight (Monoisotopic): 406.1329

AlogP: 4.22

#Rotatable Bonds: 4

Polar Surface Area: 88.26

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 6.15

CX Basic pKa: ┄

CX LogP: 3.14

CX LogD: 1.95

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.64

Np Likeness Score: -0.41

References

1. Zhang X,Zhu B,Guo L,Bakaj I,Rankin M,Ho G,Kauffman J,Lee SP,Norquay L,Macielag MJ.  (2021)  Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes.,  12  (3): [PMID:33738072] [10.1021/acsmedchemlett.0c00667]

Source

Source(1):

• Scientific Literature